LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today provided a business update highlighting continued execution of its FULCRUM-VT IDE study and FULCRUM-VT IDE sub-study, as well as progress of its previously announced review of strategic alternatives. Clinical Update To date, the Company has treated a total of 22 patients with the Com
See the full post here as oringinally posted on this site.
